View in EDS HTML Full Text

Researchers Receive Grants from NCCN Oncology Research Program Funded through Boehringer Ingelheim

Saved in:
Bibliographic Details
Title: Researchers Receive Grants from NCCN Oncology Research Program Funded through Boehringer Ingelheim
Authors: National Comprehensive Cancer Network
Source: Business Wire (English). 09/04/2012.
Abstract: The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded five research grants to investigators following NCCN ORP Scientific Review Committee analysis of proposals submitted in response to the NCCN Afatinib Request for Proposals. These grants were made possible through a $2-million research grant from Boehringer Ingelheim Pharmaceuticals, Inc. to scientifically evaluate and define the clinical effectiveness of afatinib (BIBW 2992) in solid tumors, including breast, non-small cell lung (NSCLC), and head and neck cancers. [ABSTRACT FROM PUBLISHER]
Database: Regional Business News
Full text is not displayed to guests.
FullText Text:
  Availability: 1
Header DbId: bwh
DbLabel: Regional Business News
An: bizwire.c43746291
AccessLevel: 6
PubType: News
PubTypeId: newspaperArticle
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Researchers Receive Grants from NCCN Oncology Research Program Funded through Boehringer Ingelheim
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22National+Comprehensive+Cancer+Network%22">National Comprehensive Cancer Network</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Business+Wire+%28English%29%22">Business Wire (English)</searchLink>. 09/04/2012.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded five research grants to investigators following NCCN ORP Scientific Review Committee analysis of proposals submitted in response to the NCCN Afatinib Request for Proposals. These grants were made possible through a $2-million research grant from Boehringer Ingelheim Pharmaceuticals, Inc. to scientifically evaluate and define the clinical effectiveness of afatinib (BIBW 2992) in solid tumors, including breast, non-small cell lung (NSCLC), and head and neck cancers. [ABSTRACT FROM PUBLISHER]
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=bwh&AN=bizwire.c43746291
RecordInfo BibRecord:
  BibEntity:
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Researchers Receive Grants from NCCN Oncology Research Program Funded through Boehringer Ingelheim
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: National Comprehensive Cancer Network
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 09
              Text: 09/04/2012
              Type: published
              Y: 2012
          Titles:
            – TitleFull: Business Wire (English)
              Type: main
ResultId 1